[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![trentkelp Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::633282442.png) JEFFERY @TriggeredCapital [@trentkelp](/creator/twitter/trentkelp) on x 6460 followers
Created: 2025-07-22 22:50:40 UTC

Viking Therapeutics (VKTX) is expecting to release oral data for its obesity drug VK2735 from the Phase X VENTURE-Oral Dosing Trial in the second half of 2025. The trial, which enrolled approximately XXX obese or overweight adults, evaluates the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735 dosed orally for XX weeks.

![](https://pbs.twimg.com/tweet_video_thumb/Gwfx-xrXQAAAsUo.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947791433001312280/c:line.svg)

**Related Topics**
[weight loss](/topic/weight-loss)
[$vik](/topic/$vik)
[$vktx](/topic/$vktx)

[Post Link](https://x.com/trentkelp/status/1947791433001312280)